Avoid, Moderate-High Risk
Two IGF-1 analogs in the same regimen
Two IGF-1 analogs (e.g. IGF-1 LR3 + IGF-1 DES, IGF-1 LR3 + MGF)
Why this combination is flagged
Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks
Reported risk level
Moderate-High, per peptide research and practitioner literature catalogued on PeptideHelper.org.
Peptides involved
Safer alternatives reported in literature
Pick one IGF-1 analog. IGF-1 LR3 has the longest plasma half-life and is the most-cited research analog. IGF-1 DES is shorter-acting and cited for site-of-injection effects. To layer anabolic signaling without a second IGF-1 analog, pair the chosen IGF-1 with a myostatin inhibitor (Follistatin family), these act on parallel hypertrophy pathways (PI3K/Akt vs. SMAD2/3 suppression) without compounding IGF-1R load.
Reported research framing only. Not a clinical recommendation. Consult a qualified clinician before any human use.
Frequently asked questions
Why is Two IGF-1 analogs (e.g. IGF-1 LR3 + IGF-1 DES, IGF-1 LR3 + MGF) flagged as a combination to avoid?
Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks. Reported risk level in peptide research and practitioner literature: Moderate-High.
How serious is the concern with Two IGF-1 analogs (e.g. IGF-1 LR3 + IGF-1 DES, IGF-1 LR3 + MGF)?
PeptideHelper.org categorises this combination as Moderate-High risk based on published peptide research and practitioner literature. The mechanism: Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.
What is a safer alternative to Two IGF-1 analogs (e.g. IGF-1 LR3 + IGF-1 DES, IGF-1 LR3 + MGF)?
Pick one IGF-1 analog. IGF-1 LR3 has the longest plasma half-life and is the most-cited research analog. IGF-1 DES is shorter-acting and cited for site-of-injection effects. To layer anabolic signaling without a second IGF-1 analog, pair the chosen IGF-1 with a myostatin inhibitor (Follistatin family), these act on parallel hypertrophy pathways (PI3K/Akt vs. SMAD2/3 suppression) without compounding IGF-1R load.
Which peptides are involved in this combination?
Peptides referenced by this combination on PeptideHelper.org: IGF-1 LR3, IGF-1 DES, MGF, PEG-MGF.
Open the PeptideHelper.org stack evaluator to model substitute combinations and check for class-level conflicts before any research use.
Loading interactive view…